Vivimed Labs Limited (IN:VIVIMEDLAB)
:VIVIMEDLAB
Want to see IN:VIVIMEDLAB full AI Analyst Report?
VIVIMEDLAB Stock Chart & Stats
₹4.95
₹0.00(0.00%)
At close: 4:00 PM EDT
₹4.95
₹0.00(0.00%)
Day’s Range― - ―
52-Week Range₹4.88 - ₹27.99
Previous CloseN/A
Volume151.69K
Average Volume (3M)N/A
Market Cap
₹543.09M
Enterprise Value₹4.37B
Total Cash (Recent Filing)₹489.84M
Total Debt (Recent Filing)₹3.84B
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding82,913,910
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.17
Price to Sales (P/S)0.35
P/FCF Ratio-4.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vertical Integration Across API, Formulations, ChemicalsVivimed's integrated business model — developing, manufacturing and marketing APIs, finished dosage formulations and specialty chemicals — is a durable advantage. Vertical integration can protect margins, enable cross-selling, shorten product time-to-market, and reduce supplier dependence over months to years.
Diversified Geographic Channels (domestic + Exports)Serving both domestic and export markets provides structural revenue diversification. Geographic breadth helps offset localized demand shocks, enables access to larger customer pools and long-term contract opportunities, and supports scaling of regulated product sales over the medium term.
Established Manufacturing Scale And WorkforceA manufacturing headcount of 607 indicates meaningful operational scale and manufacturing capability. That scale supports contract manufacturing, regulatory-compliant production runs and capacity to serve multiple product lines, which underpins revenue generation and operational resilience over months.
Bears Say
Sustained Revenue DeclineA pronounced and ongoing revenue decline erodes scale economics and market presence. Over a 2-6 month horizon this trend constrains pricing leverage, reduces reinvestment capacity for R&D or capacity upkeep, and makes it harder to stem margin and cash-flow deterioration without strategic change.
Collapse In Gross MarginsA drop from ~59% to ~6.7% gross margin signals structural pressure on pricing, product mix or cost control. Such a collapse undermines ability to cover fixed costs, fund commercialization or regulatory activities, and implies the company may struggle to restore sustainable profitability without major operational or portfolio changes.
Balance-sheet And Cash-flow StressNegative equity, heavy leverage metrics and sharply negative operating/ free cash flows constrain financial flexibility. Over the medium term this limits ability to invest, meet obligations, or pursue new contracts without external funding, raising solvency and restructuring risks that impair growth prospects.
Vivimed Labs Limited News
VIVIMEDLAB FAQ
What was Vivimed Labs Limited’s price range in the past 12 months?
Vivimed Labs Limited lowest stock price was ₹4.88 and its highest was ₹27.99 in the past 12 months.
What is Vivimed Labs Limited’s market cap?
Vivimed Labs Limited’s market cap is ₹543.09M.
When is Vivimed Labs Limited’s upcoming earnings report date?
Vivimed Labs Limited’s upcoming earnings report date is May 28, 2026 which is in 7 days.
How were Vivimed Labs Limited’s earnings last quarter?
Vivimed Labs Limited released its earnings results on Mar 13, 2026. The company reported -₹1.996 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.996.
Is Vivimed Labs Limited overvalued?
According to Wall Street analysts Vivimed Labs Limited’s price is currently Overvalued.
Does Vivimed Labs Limited pay dividends?
Vivimed Labs Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on Vivimed Labs Limited dividends here
What is Vivimed Labs Limited’s EPS estimate?
Vivimed Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivimed Labs Limited have?
Vivimed Labs Limited has 82,913,910 shares outstanding.
What happened to Vivimed Labs Limited’s price movement after its last earnings report?
Vivimed Labs Limited reported an EPS of -₹1.996 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.43%.
Which hedge fund is a major shareholder of Vivimed Labs Limited?
Currently, no hedge funds are holding shares in IN:VIVIMEDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivimed Labs Limited
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―
Lasa Supergenerics Ltd.
―
Parenteral Drugs (India) Limited
―